RCKT Collar Strategy
RCKT (Rocket Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
RCKT (Rocket Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $393.1M, a beta of 0.52 versus the broader market, a 52-week range of 2.19-7.14, average daily share volume of 3.4M, a public-listing history dating back to 2015, approximately 299 full-time employees. These structural characteristics shape how RCKT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.52 indicates RCKT has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a collar on RCKT?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current RCKT snapshot
As of May 15, 2026, spot at $3.25, ATM IV 119.40%, IV rank 30.51%, expected move 34.23%. The collar on RCKT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this collar structure on RCKT specifically: IV regime affects collar pricing on both sides; mid-range RCKT IV at 119.40% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 34.23% (roughly $1.11 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RCKT expiries trade a higher absolute premium for lower per-day decay. Position sizing on RCKT should anchor to the underlying notional of $3.25 per share and to the trader's directional view on RCKT stock.
RCKT collar setup
The RCKT collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RCKT near $3.25, the first option leg uses a $3.41 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RCKT chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RCKT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $3.25 | long |
| Sell 1 | Call | $3.41 | N/A |
| Buy 1 | Put | $3.09 | N/A |
RCKT collar risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
RCKT collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on RCKT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use collar on RCKT
Collars on RCKT hedge an existing long RCKT stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
RCKT thesis for this collar
The market-implied 1-standard-deviation range for RCKT extends from approximately $2.14 on the downside to $4.36 on the upside. A RCKT collar hedges an existing long RCKT position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current RCKT IV rank near 30.51% is mid-range against its 1-year distribution, so the IV signal is neutral; the collar thesis on RCKT should anchor more to the directional view and the expected-move geometry. As a Healthcare name, RCKT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RCKT-specific events.
RCKT collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RCKT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RCKT alongside the broader basket even when RCKT-specific fundamentals are unchanged. Always rebuild the position from current RCKT chain quotes before placing a trade.
Frequently asked questions
- What is a collar on RCKT?
- A collar on RCKT is the collar strategy applied to RCKT (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With RCKT stock trading near $3.25, the strikes shown on this page are snapped to the nearest listed RCKT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are RCKT collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the RCKT collar priced from the end-of-day chain at a 30-day expiry (ATM IV 119.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RCKT collar?
- The breakeven for the RCKT collar priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RCKT market-implied 1-standard-deviation expected move is approximately 34.23%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on RCKT?
- Collars on RCKT hedge an existing long RCKT stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current RCKT implied volatility affect this collar?
- RCKT ATM IV is at 119.40% with IV rank near 30.51%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.